Stock-PR Reporting FREE Daily Stock Alerts From Stock-PR.com ________________________________________       Gilead Sciences, Inc. (Nasdaq:GILD - News) announced recently that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet “Quad” regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate. The Phase III clinical program for the Quad includes [...]